BioSpace News Archive

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced plans to release its financial results for the third quarter of 2020 on November 4, 2020 after the close of the financial markets.

BiomX Inc., a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, announced the appointment of Paul Sekhri and Alan Moses, M.D., to its Board of Directors.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies, announced that the Company will present at upcoming conferences and will announce six-month safety and efficacy data from the second cohort of its AXO-Lenti-PD program the morning of Tuesday, October 6, 2020.

Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk

Educational Online Resource Offers Tools for Early Detection of Overt Hepatic Encephalopathy in Chronic Liver Disease Patients

Tabula Rasa HealthCare, Inc., a healthcare technology company advancing the field of medication safety, announced the acquisition of Personica, LLC and its subsidiaries PersonifilRx, Pharmastar and PersonifilRx New England, a provider of pharmacy services, including 340B and Medicare Part D administration solutions to Programs of All-inclusive Care for the Elderly.

Award will support advancement of ALV-304 into the clinic for the potential treatment of inflammatory bowel disease

Enrollment in first three cohorts complete; final cohort now enrolling with plans to initiate a pivotal study before year-end Data continues to support the novel immunotherapy based on B cell activation with CPI-006, including the inducement of sustained high titers of SARS-CoV-2 specific antibodies and increased levels of memory B c ell s Dose - response effect seen in first two cohorts with prolonged high titers of antibodies observed out to 56 days ; add

Encompass Health Corporation (NYSE: EHC) issued notice for redemption of all $700 million in outstanding principal balance of its 5.75% senior notes due 2024 (the “2024 Notes”)

Angel ’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program Strategic collaboration gives Corvus 49.7% equity stake and provides an opportunity to accelerate the development of the Corvus pipeline in China and globally Angel launches with $41 million financing backed by local investor group which includes three prominent biopharmaceutical companies Corvus hosting c onference c all t o